Virginia Foley, Founder of Compliance Forward

Promotional Intelligence, by Compliance Forward

Business EN ↓ 18 episodes

Our guests and topics range from Pharma/Biotech Regulatory Ad Promo insights, FDA Enforcement activities, Commercial Regulatory Strategy to pioneering approaches for compliance enablement with AI. 

Be sure to visit the podcast's website and support the creator: www.buzzsprout.com

Author

Virginia Foley, Founder of Compliance Forward

Category

Business

Podcast website

www.buzzsprout.com

Latest episode

Nov 12, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

PI: 16 Nereus Untitled Letter 12.11.2026

Virginia and Jason do a reaction-style podcast to review the letter that Vanda Pharmaceuticals received from FDA-OPDP for their 60-second TV ad for their motion-sickness prescription product, NEREUS™ (tradipitant).

PI: 15 Vectibix Warning Letter - Amgen's 2253 Mix-Up 06.11.2026

Understanding the Warning Letter to Amgen: A Process Reflection In the world of pharmaceutical marketing, compliance is paramount, and the recent warning letter issued to Amgen regarding their oncology product, Vectibix, serves as a critical reminder of this. Virginia Foley and Jason Cober discuss a warning letter that Amgen received for a video submission related to Vectibix. The letter highlight...

PI: 14 Jeuveau Untitled Letter 24.10.2026

The dynamic duo is back again. This time, get Virginia and Jason's take on the latest enforcement letter from FDA-OPDP. Jeuveau is an injectable treatment for lines and wrinkles that got issued a letter for an Instagram post. What went wrong and more importantly, how can industry get it right without specific guidance from FDA-OPDP on social media?

PI: 13 Filspari Untitled Letter 26.09.2026

Virginia Foley and Jason Cober are back from the Regulatory Affairs Professionals Society (RAPS) conference and are ready to break down the recent #FDA #OPDP Untitled Letter for FILSPARI. This letter hits on some key points: ✅ Why it's important to accurately represent approved product Indications and why minor changes in the presentation of the Indication can have major consequences ✅ Explorato...

PI: 11 (Part 2) Inside the FDA Layoffs 02.09.2026

Virginia Foley "Industry Insider" and Jason Cober "Regulatory Authority" discuss the April 2025 Reductions in Force (RIF) at HHS, specifically at FDA. Hear a first hand account about how the Reductions in Force were executed on April 1, 2025.

PI: 11 (Part 1) Inside the FDA Layoffs 02.09.2026

Virginia Foley "Industry Insider" and Jason Cober "Regulatory Authority" discuss the April 2025 Reductions in Force (RIF) at HHS, specifically at FDA. Learn about what is a RIF and why these were different.

PI: 09 Beyfortus & Tobi Podhaler Untitled Letters 02.09.2026

In the newest episode, Virginia Foley and Jason Cober discuss the recent FDA-OPDP Untitled Letters issued for BEYFORTUS and TOBI PODHALER. Unclear on how the FDA expects product Indications to be presented in promotional materials? What can patients and caregivers say about a product in a testimonial? ‪@complianceforward‬

PI: 08 A Journey in Time--Rx Drug Ads on TV 02.09.2026

We are back... this time to talk about the history of how the Adequate Provision requirement is being fulfilled with DTC drug advertising on television. The 1999 FDA guidance didn't permit DTC TV ads—yet it's being described today by FDA as a regulatory "loophole". 🧐 Spoiler: the first branded TV ad was actually in 1983, and the regulations' roots go much deeper. Virginia Foley and Jason Cober fr...

PI: 10 New Era of Enforcement w/special guest John Driscoll 02.09.2026

In this latest episode of the Promotional Intelligence podcast, Virginia Foley and Jason Cober from ‪@complianceforward‬ welcome special guest John Driscoll, Founder of OPDP Resources. Get their take on this breakout year of FDA enforcement action following the HHS announcement from September 2025 announcing the "crackdown" on DTC Rx advertising

PI: 07 From Payor Guidance to PIE and Back w/ special guest Dara Katcher Levy 02.09.2026

Virginia and Jason are joined by Dara Katcher Levy to discuss the FDA's recently revised Payor Guidance.

PI: 06 CFL Gone Wild - Vyepti Untitled Letter 02.09.2026

Jason and Virginia from ‪@complianceforward‬ complete a rapid response review of the recent enforcement letter issued for violative promotion using CFL (consistent with FDA approved labeling) data to promote efficacy claims and also PRO (patient reported outcomes) data from post-hoc analyses. Listen and learn! Like what you hear, subscribe to the Promotional Intelligence podcast to stay up-to-date...

PI: 05 Why is FDA Calling Adequate Provision a "LOOPHOLE"? 02.09.2026

The FDA's latest proposal targets what they refer to as the "adequate provision loophole" in advertising, pushing for full disclosure of risk information in TV and radio ads. What does this mean for the future of drug marketing? Application of the final rule could result in a veritable ban on DTC broadcast advertising. Expect longer ads or a shift in advertising strategies, especially towards soci...

PI: 04 What do we need to know about ELSA 4.0 - FDA's AI Tool 02.09.2026

Virginia (Industry Insider) and Jason (Regulatory Authority) discuss the FDA's recent press release announcing ELSA 4.0 - what do we know about the Agency's use of AI and what remains unknown? AI is transforming industries, and the FDA is no exception. With the recent announcement of ELSA 4.0, the FDA has taken a significant step forward in integrating AI into its review processes. But what does t...

PI: 12 ASA-3000 Untitled Letter - Pre-approval Promotion 02.09.2026

Virginia and Jason from  @complianceforward  discuss the August 2026 Untitled Letter issued by OPDP for pre-approval promotion of ASA-3000 - an investigational product. This letter includes several key violations and highlights the importance of ensuring medical communication regarding investigational products - especially those in the pre-approval phase - remains non-promotional.

PI: 03 - Photofrin Untitled Letter (June 22, 2026) 07.07.2026

Virginia (Industry Insider) and Jason (Regulatory Authority) breakdown the details of the Photofrin Untitled Letter issued by OPDP on June 22, 2026.

PI: 02 (Part 2) - Oncology Time-to-Event Endpoints 07.07.2026

In Part 2 of this episode Jason Cober (Regulatory Authority) and Virginia Foley (Industry Insider) continue the conversation and talk about the trend of FDA enforcement in oncology time-to-event data presentations in the recent bolus of letters, coming from both CDER and CBER.

PI: 02 (Part 1) - Oncology Time-to-Event Endpoints 07.07.2026

Jason Cober (The Regulatory Authority) and Virginia Foley (The Industry Insider) from  @complianceforward  take a deep dive into the world of time-to-event endpoints as measured by single-arm trials. They dissect the FDA's position on development of these types of clinical trials and explain why the promotional enforcement letters are stacking up. Enjoy part 1 and stay tuned for part 2.

PI Episode 1 - SUCRAID Untitled Letter 04.06.2026

In this episode, Jason and Virginia break down the recent enforcement letter regarding Sucraid, highlighting its misleading promotional materials. The FDA has flagged two emails targeting healthcare professionals for their claims about the product's indication and presentation of safety. We dive into the details—what was wrong with the promotional emails?  And what should be done differently to en...

Listen to the Promotional Intelligence, by Compliance Forward podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.